Introduction
Meniere’s disease(MD) is an idiopathic inner ear disorder characterized
by episodic attacks of vertigo, fluctuating hearing loss, tinnitus, and
aural fullness. MD exhibits a relapsing-remitting pattern, with episodic
attacks terminated by periods of restitution to normal auditory and
vestibular function. Additionally, auditory and vestibular function
decline over time.Although the pathophysiologic mechanism of MD is well
accepted, the underlying causes remains uncertain1. MD
treatment is still objective of controversies in literature and it must
be first based on a trustable diagnosis, as recommended by guidelines
and classification of the AAO-HSN published in 19952and reviewed by the Equilibrium Committee in 20153.
MD has a considerable negative effect on patient’s quality of life so
current therapies are directed to prevent or reduce the frequency and
severity of vertigo crises4. Intratympanic injection
of gentamicin(ITG) is considered the treatment of choice in patients
with refractory disease1,4. However due to its
possible hearing side effects there is still no general consensus on
dose and timing of ITG4.
The aim of our study is to evaluate the effectiveness of intratympanic
injection of gentamicin on vertigo control with close doses and its
hearing effects.